AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Procept Biorobotics Corp (NASDAQ:PRCT)
22.1 USD
-1.120 4.823%Sponsored Reports
Loading...
| Previous Close (in USD) | 23.22 |
|---|---|
| Change | -1.120 4.823% |
| 52 W H/L (in USD) | 103.810/47.040 |
| EBITDA (in USD) | -90.878M |
| PE Ratio | -- |
| Volume | 3466829 |
| Diluted Eps TTM | -1.69 |
| Total Assets (in USD) | 534.017M |
|---|---|
| Total Liabilities (in USD) | 131.797M |
| Revenue TTM (in USD) | 249.121M |
| Cash (in USD) | 333.725M |
| Market Cap (in USD) | 3,212.938 M |
| Revenue Per Share TTM | 4.691 |
| Gross Profit TTM (in USD) | 156.226M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Procept Biorobotics Corp
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
150 Baytech Drive, San Jose, CA, United States, 95134
650 232 7200
Employees: 756
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Reza Zadno Ph.D. | Pres, CEO & Director | 1955 |
| 2. | Mr. Kevin Waters | Exec. VP & CFO | 1977 |
| 3. | Mr. Hisham Shiblaq | Exec. VP & Chief Commercial Officer | 1976 |
| 4. | Mr. Mohan F. Sancheti | Sr. VP of Operations | 1964 |
| 5. | Ms. Alaleh Nouri | EVP, Chief Legal Officer & Corp. Sec. | 1979 |
| 6. | Ms. Minni Vittal | Sr. VP & Chief People Officer | NA |
| 7. | Mr. Bijesh Chandran | Sr. VP of Regulatory Affairs & Quality Assurance | NA |
| 8. | Mr. Barry Templin | Sr. VP of Clinical & Medical Affairs | NA |
| 9. | Dr. Thomas J. Yorkey Ph.D. | Sr. VP of R&D | 1962 |
| 10. | Dr. Reza Zadno Ph.D. | President, CEO & Director | 1955 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+1.950 2.199% | 89.355 | 25.970 | 17.241 | 3.570 | 3.200 | 3.805 | 16.753 |
|
SYK
Stryker Corporation |
+2.640 0.857% | 309.24 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
+0.940 1.169% | 81.3 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+0.160 0.342% | 47.25 | 31.490 | 17.241 | 4.407 | 3.650 | 4.878 | 19.194 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -87.154M | -59.853M | -53.019M | -41.975M |
| Minority Interest | - | - | - | - |
| Net Income | -93.584M | -62.384M | -58.255M | -42.653M |
| Selling General Administrative | 88.828M | 51.036M | 30.272M | 28.518M |
| Gross Profit | 37.085M | 15.865M | -1.255M | -1.885M |
| Reconciled Depreciation | 2.841M | 3.324M | 2.86M | 1.494M |
| Ebit | -80.724M | -54.164M | -47.802M | -43.55M |
| Ebitda | -78.713M | -54.043M | -44.783M | -40.953M |
| Depreciation And Amortization | 2.011M | 0.121M | 3.019M | 2.597M |
| Operating Income | -80.724M | -54.164M | -47.802M | -43.55M |
| Other Operating Expenses | 155.738M | 88.637M | 55.519M | 49.719M |
| Interest Expense | 5.183M | 5.81M | 5.261M | 0.724M |
| Tax Provision | - | - | - | - |
| Interest Income | 2.497M | 0.121M | 0.184M | 1.149M |
| Net Interest Income | -2.686M | -5.689M | -5.077M | 0.425M |
| Income Tax Expense | 6.43M | 2.531M | 5.236M | 0.678M |
| Total Revenue | 75.014M | 34.473M | 7.717M | 6.169M |
| Total Operating Expenses | 117.809M | 70.029M | 46.547M | 41.665M |
| Cost Of Revenue | 37.929M | 18.608M | 8.972M | 8.054M |
| Total Other Income Expense Net | -6.43M | -5.689M | -5.217M | 1.575M |
| Net Income From Continuing Ops | -87.154M | -59.853M | -53.019M | -41.975M |
| Net Income Applicable To Common Shares | -87.154M | -59.853M | -53.019M | -41.975M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Total Assets | 534.017M | 404.717M | 309.329M | 337.024M | 125.971M |
| Intangible Assets | 0.932M | 1.204M | 1.477M | 1.75M | - |
| Other Current Assets | 8.453M | 5.213M | 6.175M | 4.242M | 0.731M |
| Total Liab | 131.797M | 123.965M | 112.257M | 69.932M | 308.865M |
| Total Stockholder Equity | 402.22M | 280.752M | 197.072M | 267.092M | -182.894M |
| Other Current Liab | 29.558M | 25.089M | 20.915M | 11.082M | 6.794M |
| Common Stock | - | - | - | -337.024M | - |
| Capital Stock | 0M | 0M | 0M | 0M | 0M |
| Retained Earnings | -545.985M | -454.572M | -348.675M | -261.521M | -201.668M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0M | 3.089M | 0.777M | 0.777M |
| Cash | 333.725M | 257.222M | 221.859M | 304.32M | 100.13M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 53.133M | 45.927M | 35.29M | 16.241M | 14.526M |
| Current Deferred Revenue | 9.565M | 5.656M | 2.855M | 1.025M | 0.233M |
| Net Debt | -253.475M | -178.018M | -144.542M | -250.22M | -45.368M |
| Short Term Debt | 1.91M | 1.683M | 2.129M | 2.105M | 6.259M |
| Short Long Term Debt | - | - | - | - | 4.551M |
| Short Long Term Debt Total | 80.25M | 79.204M | 77.317M | 54.1M | 54.762M |
| Other Stockholder Equity | 948.205M | 735.24M | 545.753M | 191.642M | 18.788M |
| Property Plant Equipment | - | - | 32.137M | 8.324M | 12.915M |
| Total Current Assets | 481.842M | 350.567M | 272.626M | 326.173M | 110.256M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 83.496M | 48.376M | 15.272M | 4.464M | 1.549M |
| Long Term Debt | 51.472M | 51.339M | 51.213M | 50.004M | 44.407M |
| Inventory | 56.168M | 39.756M | 28.543M | 13.147M | 7.477M |
| Accounts Payable | 10.032M | 13.499M | 9.391M | 2.029M | 1.24M |
| Accumulated Other Comprehensive Income | - | 0.084M | -0.006M | -0.053M | -0.014M |
| Non Currrent Assets Other | 5.593M | 0.919M | 3.089M | 0.777M | 0.777M |
| Non Current Assets Total | 52.175M | 54.15M | 36.703M | 10.851M | 15.715M |
| Capital Lease Obligations | 28.778M | 27.865M | 26.104M | 4.096M | 5.804M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -2.653M | -0.592M | -0.233M | 50.764M |
| Total Cashflows From Investing Activities | -2.653M | -0.592M | -0.233M | 43.153M |
| Total Cash From Financing Activities | 3.612M | 262.116M | 106.771M | 26.527M |
| Net Income | -87.154M | -59.853M | -53.019M | -41.975M |
| Change In Cash | -79.423M | 204.19M | 58.195M | 25.862M |
| Begin Period Cash Flow | 305.097M | 100.907M | 42.712M | 16.85M |
| End Period Cash Flow | 225.674M | 305.097M | 100.907M | 42.712M |
| Total Cash From Operating Activities | -80.382M | -57.334M | -48.343M | -43.818M |
| Depreciation | 2.841M | 3.324M | 2.86M | 1.494M |
| Other Cashflows From Investing Activities | - | - | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | -15.251M | -6.124M | -3.105M | -5.074M |
| Sale Purchase Of Stock | 2.409M | 177.406M | - | - |
| Other Cashflows From Financing Activities | 50.195M | 89.752M | -0.233M | 43.153M |
| Capital Expenditures | 2.653M | 0.592M | 0.233M | 7.611M |
| Change In Working Capital | -11.487M | -4.707M | -0.483M | -3.532M |
| Other Non Cash Items | 5.081M | -0.345M | -0.097M | -1.799M |
| Free Cash Flow | -83.035M | -57.926M | -48.576M | -51.429M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl S | 1 year ago | 2159194 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1644060 |
| 3. | Fidelity Growth Company Fund | 1 year ago | 1362826 |
| 4. | Vanguard Small Cap Index | 1 year ago | 1297222 |
| 5. | iShares Russell 2000 ETF | 1 year ago | 1099458 |
| 6. | Fidelity Select Medical Tech and Devcs | 1 year ago | 1080149 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 829476 |
| 8. | Fidelity Select Health Care | 1 year ago | 743820 |
| 9. | Vanguard Small Cap Growth Index Inv | 1 year ago | 722398 |
| 10. | Fidelity Small Cap Growth | 1 year ago | 669370 |
| 11. | Champlain Small Company Fund, LLC | 1 year ago | 659120 |
| 12. | Franklin Innovation Composite | 1 year ago | 650000 |
| 13. | AB Small Cap Growth A | 1 year ago | 633958 |
| 14. | Global X Robotics & Artfcl Intllgnc ETF | 1 year ago | 598124 |
| 15. | T. Rowe Price Health Sciences | 1 year ago | 497209 |
| 16. | Fidelity Growth Company K6 | 1 year ago | 483356 |
| 17. | T. Rowe Price Small-Cap Stock | 1 year ago | 482065 |
| 18. | T. Rowe Price US Small-Cap Core Equity | 1 year ago | 482065 |
| 19. | AB Discovery Growth A | 1 year ago | 449617 |
| 20. | Fidelity Small Cap Index | 1 year ago | 442668 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 1 year ago | 8222688 |
| 2. | Vanguard Group Inc | 1 year ago | 5127137 |
| 3. | BlackRock Inc | 1 year ago | 3876388 |
| 4. | AllianceBernstein L.P. | 1 year ago | 1752478 |
| 5. | State Street Corp | 1 year ago | 1187261 |
| 6. | Loomis, Sayles & Company LP | 1 year ago | 1181300 |
| 7. | Geode Capital Management, LLC | 1 year ago | 1164037 |
| 8. | T. Rowe Price Investment Management,Inc. | 1 year ago | 985942 |
| 9. | Wellington Management Company LLP | 1 year ago | 962235 |
| 10. | Artisan Partners Limited Partnership | 1 year ago | 939459 |
| 11. | Morgan Stanley - Brokerage Accounts | 1 year ago | 757400 |
| 12. | Westfield Capital Management Company, L.P. | 1 year ago | 748557 |
| 13. | JPMorgan Chase & Co | 1 year ago | 716333 |
| 14. | T. Rowe Price Associates, Inc. | 1 year ago | 713856 |
| 15. | Champlain Investment Partners, LLC | 1 year ago | 676196 |
| 16. | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 1 year ago | 631134 |
| 17. | Bank of America Corp | 1 year ago | 623408 |
| 18. | D. E. Shaw & Co LP | 1 year ago | 607353 |
| 19. | AXA SA | 1 year ago | 582366 |
| 20. | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1 year ago | 551767 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...